Sino Biopharmaceutical (OTCMKTS:SBMFF – Get Free Report) is expected to announce its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.0086 per share and revenue of $2.0675 billion for the quarter.
Sino Biopharmaceutical Price Performance
OTCMKTS SBMFF opened at $0.83 on Thursday. Sino Biopharmaceutical has a 52 week low of $0.44 and a 52 week high of $1.24. The company has a quick ratio of 1.28, a current ratio of 1.36 and a debt-to-equity ratio of 0.07. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $0.91.
About Sino Biopharmaceutical
Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.
The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.
Read More
Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
